Higuchi Takahiro, Taki Junichi, Sumiya Hisashi, Kinuya Seigo, Nakajima Kenichi, Namura Masanobu, Tonami Norihisa
Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences, Japan.
Ann Nucl Med. 2005 Apr;19(2):95-9. doi: 10.1007/BF03027387.
Histological diagnosis and grading of cartilaginous tumors are closely correlated with patient prognosis; consequently, they are essential elements. We attempted to clarify the characteristics of 201Tl uptake in various histological types of cartilaginous tumors and to assess its clinical value.
Twenty-two cases with histologically proven cartilaginous tumors (3 enchondromas, 15 conventional chondrosarcomas (grade I = 9, II = 5, III = 1), 3 mesenchymal chondrosarcomas, and 1 de-differentiated chondrosarcoma) were examined retrospectively. Planar 201Tl images were recorded 15 min following intravenous injection of 201Tl (111 MBq). 201Tl uptake in the tumor was evaluated visually employing a five-grade scoring system: 0 = no appreciable uptake, 1 = faint uptake above the background level, 2 = moderate uptake, 3 = intense uptake but lower than heart uptake and 4 = uptake higher than heart uptake.
201Tl uptake scores were 0 in 3 of 3 enchondromas, 9 of 9 grade I, and 4 of 5 grade II conventional chondrosarcomas. 201Tl uptake scores were 1 among 1 of 5 grades II and a grade III conventional chondrosarcoma. Mesenchymal chondrosarcoma and de-differentiated chondrosarcoma displayed 201Tl uptake scores of 2 or 3.
Absence of elevated 201Tl uptake in cartilaginous tumors was indicative of enchondroma or low-grade conventional chondrosarcoma. However, in instances in which 201Tl uptake is obvious, high-grade chondrosarcoma or variant types should be considered.
软骨肿瘤的组织学诊断和分级与患者预后密切相关;因此,它们是关键要素。我们试图阐明不同组织学类型软骨肿瘤中铊-201摄取的特征,并评估其临床价值。
回顾性研究22例经组织学证实的软骨肿瘤病例(3例内生软骨瘤、15例传统型软骨肉瘤(I级=9例,II级=5例,III级=1例)、3例间叶性软骨肉瘤和1例去分化软骨肉瘤)。静脉注射铊-201(111MBq)15分钟后记录平面铊-201图像。采用五级评分系统对肿瘤中的铊-201摄取进行视觉评估:0=无明显摄取,1=高于背景水平的微弱摄取,2=中度摄取,3=强烈摄取但低于心脏摄取,4=摄取高于心脏摄取。
3例内生软骨瘤中的3例、9例I级中的9例以及5例II级传统型软骨肉瘤中的4例铊-201摄取评分为0。5例II级中的1例和1例III级传统型软骨肉瘤的铊-201摄取评分为1。间叶性软骨肉瘤和去分化软骨肉瘤的铊-201摄取评分为2或3。
软骨肿瘤中铊-201摄取未升高提示内生软骨瘤或低级别传统型软骨肉瘤。然而,在铊-201摄取明显的情况下,应考虑高级别软骨肉瘤或变异型。